Fluticasone Furoate PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Activates intracellular glucocorticoid receptors and suppresses inflammatory cytokines and mediator release in airway and nasal tissues. The clinical mechanism depends on the route and whether fluticasone furoate is used alone or in a fixed combination.
Indications / reported uses
Treatment of allergic rhinitis symptoms with intranasal fluticasone furoate products
Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) only in authorised fixed combinations with a long-acting bronchodilator; fluticasone monotherapy and combination-product indications are not interchangeable
Identification source:PubChem record (CID 9854489). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fluticasone Furoate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluticasone Furoate Permitted Daily Exposure (PDE) report (the Fluticasone Furoate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluticasone Furoate Occupational Exposure Limit (OEL) report (the Fluticasone Furoate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.